BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38155480)

  • 1. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
    Lee JC; Li CF; Huang HY; Zhu MJ; Mariño-Enríquez A; Lee CT; Ou WB; Hornick JL; Fletcher JA
    J Pathol; 2017 Feb; 241(3):316-323. PubMed ID: 27874193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
    Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
    Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
    Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
    Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
    Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
    Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.
    Jiang Q; Tong HX; Hou YY; Zhang Y; Li JL; Zhou YH; Xu J; Wang JY; Lu WQ
    Orphanet J Rare Dis; 2017 May; 12(1):97. PubMed ID: 28535796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
    Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
    Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
    [No Abstract]   [Full Text] [Related]  

  • 16. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT).
    Sommer S; Schmutz M; Schaller T; Mayr P; Dintner S; Märkl B; Huss R; Golas MM; Kuhlen M; Jordan F; Claus R; Heinrich B
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1916. PubMed ID: 37950626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
    Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
    Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.